Activiomics Ltd., a London, UK-based developer of innovative technologies for identifying drug biomarkers and developing and profiling drug candidates, has received an over over £500,000 equity investment.
The round was led by IP Group plc (LSE: ipo), with participation from IP Venture Fund and members of Activiomics’ management.
The company intends to use the funds to strengthen its ability to grow its partnerships with pharmaceutical and biotechnology companies and to pursue the identification of novel predictive and prognostic markers in oncology and inflammation using its proprietary technology.
Incorporated in February 2010 and led by CEO Mark Warne, Activiomics commercializes its technology by partnering directly with pharma and biotech companies on bespoke programmes of work. The company has signed revenue generating partnerships with GlaxoSmithKline, UCB and Genentech.